# Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin

> **NCT02169440** · PHASE1 · COMPLETED · sponsor: **Bial - Portela C S.A.** · enrollment: 20 (actual)

## Conditions studied

- Parkinson's Disease (PD)

## Interventions

- **DRUG:** BIA 9-1067
- **DRUG:** Warfarin

## Key facts

- **NCT ID:** NCT02169440
- **Lead sponsor:** Bial - Portela C S.A.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-06
- **Primary completion:** 2009-07
- **Final completion:** 2009-07
- **Target enrollment:** 20 (ACTUAL)
- **Last updated:** 2015-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02169440

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02169440, "Effect of BIA 9-1067 on the Pharmacokinetics and Pharmacodynamics of Warfarin". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02169440. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*